Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Protocol Title: Randomized open label study comparing the metabolic control of first Kidney
Transplant recipients with Type 2 Diabetes Mellitus (DM) receiving either Prograf or Neoral
as part of a ATG induction, prednisone free and blood monitored Cellcept immunosuppressive
regimen.
PURPOSE This is a single center medical research study to analyze post-transplant kidney
recipients with pre-existing type 2 diabetes managed according to the recommended American
Diabetes Association (ADA) guidelines. Prograf (Tac) and Neoral (CSA) are the two main
medications to prevent rejection after transplantation. However, they may contribute to
poorer diabetes control. The purpose of the study is to compare the effects of Prograf and
Neoral on the control of Diabetes after kidney transplantation. In addition, all participants
in this study will receive Thymoglobulin (anti-lymphocyte globulin) at the time of
transplantation instead of long term prednisone (steroids).